Zimmer Partners LP Has $2.88 Million Stock Position in Immatics (NASDAQ:IMTX)

Zimmer Partners LP raised its stake in Immatics (NASDAQ:IMTX - Free Report) by 44.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 405,000 shares of the company's stock after buying an additional 125,000 shares during the quarter. Zimmer Partners LP owned 0.34% of Immatics worth $2,880,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IMTX. Vestal Point Capital LP grew its holdings in shares of Immatics by 67.3% during the 4th quarter. Vestal Point Capital LP now owns 6,275,000 shares of the company's stock valued at $44,615,000 after acquiring an additional 2,525,000 shares in the last quarter. Suvretta Capital Management LLC acquired a new stake in Immatics during the fourth quarter valued at $36,014,000. Sphera Funds Management LTD. boosted its position in Immatics by 27.7% during the fourth quarter. Sphera Funds Management LTD. now owns 921,111 shares of the company's stock valued at $6,549,000 after purchasing an additional 200,000 shares during the last quarter. Paradigm Biocapital Advisors LP grew its stake in Immatics by 38.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 5,414,409 shares of the company's stock valued at $38,496,000 after purchasing an additional 1,509,547 shares in the last quarter. Finally, Orbimed Advisors LLC increased its position in Immatics by 53.9% in the 4th quarter. Orbimed Advisors LLC now owns 3,087,462 shares of the company's stock worth $21,952,000 after purchasing an additional 1,081,081 shares during the last quarter. Hedge funds and other institutional investors own 64.41% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on IMTX. Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st. Wall Street Zen lowered shares of Immatics from a "hold" rating to a "strong sell" rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $17.00.

Immatics Trading Down 1.7%

IMTX stock traded down $0.09 during midday trading on Monday, hitting $5.11. The stock had a trading volume of 375,092 shares, compared to its average volume of 653,124. Immatics has a 52 week low of $3.30 and a 52 week high of $13.77. The stock has a 50-day simple moving average of $4.52 and a 200 day simple moving average of $5.68. The firm has a market capitalization of $621.12 million, a price-to-earnings ratio of -7.74 and a beta of 0.87.

Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.04. The company had revenue of $20.12 million during the quarter, compared to the consensus estimate of $14.92 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. On average, equities analysts forecast that Immatics will post -0.72 EPS for the current year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.